GRI — GRI Bio Inc.
NASDAQ · Healthcare · Biotechnology
$1.87
-$0.04 (-1.85%)
GRI Bio Inc. (GRI) is a biotechnology company listed on NASDAQ. It is led by W. Marc Hertz Ph.D., based in 2223 Avenida de la Playa, La Jolla, CA, United States, 92037, with about 3 employees. GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Net income was -$3.4M. GRI currently screens at market cap $3.5M and trailing P/E 0.1.
Use this GRI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GRI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GRI SEC filings page. Lician reads the product cache first so this HTML stays unique to GRI Bio Inc. even when a live quote feed is slow.
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Key Statistics
Market Cap
$3.54M
Volume
114,807
Previous Close
$1.79
Day Range
$1.78 – $1.98
P/E Ratio
0.05
EPS
-$55.21
Revenue
$0.00
Net Income
-$8.21M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
3
GRI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.21M | -$13.04M | -$3.22M | -$9.30M |
| EPS (Diluted) | -$55.21 | -$5.02K | -$24.95 | -$1.42 |
Total Assets
$5.74M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$5.03M
Operating Cash Flow
-$8.61M
Free Cash Flow
$0.00
GRI Bio Inc. Company Information
- Co-Founder, CEO, President & Director
- W. Marc Hertz Ph.D.
- Headquarters
- 2223 Avenida de la Playa, La Jolla, CA, United States, 92037
- Website
- www.gribio.com
- Phone
- 619 400 1170
- IPO / Founded
- 2021-02-10
- Sector
- Healthcare
- Industry
- Biotechnology